Edition:
United Kingdom

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

1.95USD
20 Aug 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.95
Open
$1.94
Day's High
$1.94
Day's Low
$1.94
Volume
2
Avg. Vol
11,650
52-wk High
$11.90
52-wk Low
$1.71

Latest Key Developments (Source: Significant Developments)

Akari Therapeutics Qtrly Loss Per Common Share $0.01
Wednesday, 21 Mar 2018 

March 21 (Reuters) - Akari Therapeutics Plc ::AKARI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS.AKARI THERAPEUTICS PLC - CAPSTONE, PHASE III NAÏVE PNH TRIAL EXPECTED TO OPEN IN Q1 2018.AKARI THERAPEUTICS - BASED ON CURRENT CASH POSITION AND OPERATING PLAN, EXPECTS HAS SUFFICIENT CASH TO FUND OPERATIONS INTO Q2 2019.AKARI THERAPEUTICS PLC - AS OF DECEMBER 31, 2017, COMPANY HAD CASH AND CASH EQUIVALENTS OF $28.1 MILLION.AKARI THERAPEUTICS PLC - QTRLY LOSS PER COMMON SHARE $0.01.  Full Article

Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Akari Therapeutics Plc ::AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT.AKARI THERAPEUTICS PLC - NEW DOSING REGIMEN AT 45 MG PER DAY IS EXPECTED TO BE USED IN PHASE III TRIALS.AKARI - PLANS TO COMMENCE TWO PHASE III PNH CLINICAL TRIALS WITH COVERSIN BEGINNING WITH CAPSTONE IN Q1 OF 2018.AKARI THERAPEUTICS PLC - ON TRACK TO PROGRESS INTO PHASE III CLINICAL TRIALS IN Q1 OF 2018.AKARI THERAPEUTICS PLC - SECOND PHASE III TRIAL, ASSET, IS PLANNED FOR H2 2018 & WILL INCLUDE SOLIRIS SWITCH PATIENTS.  Full Article

Akari Therapeutics says priced public offering of american depositary shares
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Akari Therapeutics Plc :Akari therapeutics announces pricing of public offering of american depositary shares.Akari therapeutics plc - priced public offering of 3.5 million american depositary shares, or adss, at $5.00 per ads​.  Full Article

BRIEF-David Horn Solomon Resigns As CEO Of Akari Therapeutics

* AKARI THERAPEUTICS SAYS ON MAY 8, DAVID HORN SOLOMON, RESIGNED AS CEO AND AS A MEMBER OF BOARD EFFECTIVE IMMEDIATELY - SEC FILING